BMRN vs NRXS · P/E 40, rev $1.76B vs rev $3.6M
Biomarin Pharmaceutical Inc (BMRN) versus Neuraxis, Inc. (NRXS) — a side-by-side from cached financials, not a winner call.
Biomarin Pharmaceutical Inc (BMRN) is a biotechnology company listed on NASDAQ.
Neuraxis, Inc. (NRXS) is a biotechnology company listed on AMEX.
Latest reported BMRN revenue for 2026-06-30 was $1.76B. Net income was $150.3M. BMRN currently screens at market cap $10.63B and trailing P/E 39.6.
Latest reported NRXS revenue for 2025-12-31 was $3.6M. Net income was -$7.8M. Revenue was up 32.9% from 2024-12-31 to 2025-12-31. NRXS currently screens at market cap $83.1M.
BMRN currently screens at market cap $10.63B and trailing P/E 39.6. NRXS currently screens at market cap $83.1M.
Not investment advice. Open the BMRN and NRXS stock pages for the full models.
Not investment advice.